Immuneering Corporation Class A Common Stock (IMRX) Stock Price

IMRXStock

$4.99−10.89%52W

Market Cap$322.84M

P/E—

PEG Ratio—

Div yield—

Beta0.33

IMRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-14.09%

Price vs S&P 500 (4W)18.12%

VGM Score35.46

Book Value / Share (Quarterly)$2.95

P/TBV (Annual)1.95x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.88

Price vs S&P 500 (YTD)-36.99%

Gross Margin (TTM)28.00%

Net Profit Margin (TTM)-9610.00%

EPS (TTM)$-1.03

10-Day Avg Trading Volume0.55M

EPS Excl Extra (TTM)$-1.03

EPS (Annual)$-2.03

ROI (Annual)-147.39%

Gross Margin (Annual)50.00%

Cash / Share (Quarterly)$2.32

ROA (Last FY)-115.72%

EBITD / Share (TTM)$-1.08

ROE (5Y Avg)-64.35%

Operating Margin (TTM)-9778.00%

Cash Flow / Share (Annual)$-1.77

P/B Ratio1.76x

P/B Ratio (Quarterly)1.69x

Net Income / Employee (Annual)$-1,150,900

EV / Revenue (TTM)590.20x

Net Interest Coverage (TTM)-25.59x

ROA (TTM)-25.74%

EPS Incl Extra (Annual)$-2.03

Current Ratio (Annual)17.50x

Quick Ratio (Quarterly)18.47x

3-Month Avg Trading Volume1.26M

52-Week Price Return-10.89%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.94

P/S Ratio (Annual)1051.33x

Asset Turnover (Annual)0.00x

52-Week High$10.08

EPS Excl Extra (Annual)$-2.03

CapEx CAGR (5Y)23.25%

26-Week Price Return-2.16%

Quick Ratio (Annual)17.16x

13-Week Price Return-1.38%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)19.47x

Enterprise Value$295.10M

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-15784.38%

Cash / Share (Annual)$1.16

3-Month Return Std Dev78.26%

Net Income / Employee (TTM)$-1,080,700

ROE (Last FY)-147.39%

EPS Basic Excl Extra (Annual)$-2.03

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.03

Receivables Turnover (Annual)3.20x

ROI (TTM)-27.15%

P/S Ratio (TTM)672.85x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.32

Price vs S&P 500 (52W)-29.45%

Year-to-Date Return-24.16%

5-Day Price Return-3.67%

EPS Normalized (Annual)$-2.03

ROA (5Y Avg)-54.72%

Net Profit Margin (Annual)-15784.38%

Month-to-Date Return20.82%

Cash Flow / Share (TTM)$-1.85

EBITD / Share (Annual)$-2.12

Operating Margin (Annual)-16168.75%

ROI (5Y Avg)-64.35%

EPS Basic Excl Extra (TTM)$-1.03

P/TBV (Quarterly)1.70x

P/B Ratio (Annual)1.94x

Pretax Margin (TTM)-9672.00%

Book Value / Share (Annual)$1.33

Price vs S&P 500 (13W)-3.34%

Beta0.33x

Revenue / Share (TTM)$0.00

ROE (TTM)-27.15%

52-Week Low$3.86

vGradeD

mGradeC

vgmGradeD

IMRX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.27	-$0.27	-0.53%(-$0.00)
Q1 2026	May 15, 2026	-$0.25	-$0.21	+16.67%(+$0.04)
Q4 2025	Mar 6, 2026	-$0.31	-$0.18	+42.25%(+$0.13)
Q3 2025	Nov 12, 2025	-$0.39	-$0.38	+2.15%(+$0.01)
Q2 2025	Aug 13, 2025	-$0.40	-$0.40	-0.50%(-$0.00)

IMRX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.25

4.23

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
IMRXImmuneering Corporation Class A Common Stock	D	—	C	$4.99
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Immuneering Corporation Class A Common Stock

Immuneering is a biopharmaceutical company developing oncology and neurology treatments using its proprietary Disease Cancelling Technology platform, which leverages computational biology and translational bioinformatics. The company generates revenue from both internal drug discovery programs and by licensing its computational capabilities to other pharmaceutical and biotechnology companies.